Bioactivity diversity and functional mechanism of tetrahydroisoquinoline alkaloids

Yaoxue Xuebao

Volumn 45, Issue 1, 2010, Pages 9-16

  Liu, Ce Jia ^a   Liu, Dian Yu ^a   Xiang, Lan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bioactivity diversity; Functional mechanism; Tetrahydroisoquinoline alkaloids

Indexed keywords

TETRAHYDROISOQUINOLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BRONCHODILATATION; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; IC 50; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BRONCHODILATOR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; TETRAHYDROISOQUINOLINES;

EID: 77950612702     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Gu H. Biomimetic Synthesis of Mannich Alkali, Tetrahydroisoquinoline and Tetrahydro-β-Carboline (Mannich -β-) [D]. Xi-an: Northwest University, 2007.
2. Scott JD, Williams RM. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics [J]. Chem Rev, 2002, 102: 1669-1730. (Pubitemid 35377652)
3. Xiang L, Xing DM, Wang W, et al. Alkaloids from Portulaca oleracea L. [J]. Phytochemistry, 2005, 66: 2595-2601.
4. Wang RF, Yang XW, Ma CM, et al. A bioactive alkaloid from the flowers of Trollius chinensis [J]. Heterocycles, 2004, 63: 1443-1448.
5. Zhao YX, Ding XB. Studies on the alkaloids from Salsola collina Pall [J]. Acta Pharm Sin. 2004, 39: 598-600.
6. Yang ZJ, Liu CJ, Xiang L, et al. Phenolic alkaloids as a new class of antioxidants in Portulaca oleracea [J]. Phytother Res. 2009, 23: 1032-1035.
7. Tewari D, Saffari B, Cowan C, et al. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma [J]. Gynecol Oncol, 2006, 102: 421-424. (Pubitemid 44353657)
8. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer [J]. Eur J Cancer, 2009, 45: 1153-1161.
9. McMeekin DS, Lisyanskaya A, Crispens M, et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study [J]. Gynecol Oncol, 2009, 114: 288-292.
10. David-Cordonnier MH, Gajate C, Olmea O, et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin [J]. Chem Biol, 2005, 12: 1201-1210. (Pubitemid 41628255)
11. Lee JK, Leslie EM, Zamek-Gliszczynski MJ, et al. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance- associated proteins (Mrps) may prevent hepatotoxicity [J]. Toxicol Appl, 2008, 228: 17-23.
12. Aubry S, Pellet-Rostaing S, dit Chabert JF, et al. Synthesis and inhibition of cancer cell proliferation of (1,3)-bis-tetrahydroisoquinolines and piperazine systems [J]. Bioorg Med Chem Lett, 2007, 17: 2598-2602.
13. Mohler ML, Kang GS, Hong SS, et al. Discovery of antiglioma activity of biaryl 1, 2, 3, 4-tetrahydroisoquinoline derivatives and conformationally flexible analogues [J]. J Med Chem, 2006, 49: 5845-5848.
14. Lin HR, Safo MK, Abraham DJ. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer [J]. Bioorg Med Chem Lett, 2007, 17: 2581-2589.
15. Porter J, Payne A, de Candole B, et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors [J]. Bioorg Med Chem Lett, 2009, 19: 230-233.
16. Tarby CM, Kaltenbach RF 3rd, Huynh T, et al. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyltetrahydroisoquinoline lead series [J]. Bioorg Med Chem Lett, 2006, 16: 2095-2100.
17. Choquette D, Teffera Y, Polverino A, et al. Discovery of novel 1, 2, 3, 4-tetrahydro-isoquinolines and 3, 4-dihydroisoquinoline-1 (2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties [J]. Bioorg Med Chem Lett, 2008, 18: 4054-4058.
18. Kashiwada Y, Aoshima A, Ikeshiro Y, et al. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids [J]. Bioorg Med Chem, 2005, 13: 443-448. (Pubitemid 39642926)
19. Iwasa K, Moriyasu M, Tacbibana Y, et al. Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents [J]. Bioorg Med Chem, 2001, 9: 2871-2884. (Pubitemid 32904532)
20. Cheng P, Huang N, Jiang ZY, et al. 1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agent in vitro [J]. Bioorg Med Chem Lett, 2008, 18: 2475-2478.
21. Chen KX, Xie HY, Li ZG, et al. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents [J]. Bioorg Med Chem Lett, 2008, 18: 5381-5386.
22. Zhu J, Lu J, Zhou Y, et al. Design, synthesis, and antifungal activities in vitro of novel tetrahydroisoquinoline compounds based on the structure of lanosterol 14α-demethylase (CYP51) of fungi [J]. Bioorg Med Chem Lett, 2006, 16: 5285-5289. (Pubitemid 44332226)
23. Tsoyi K, Kim HJ, Shin JS, et al. HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride [J]. Cell Signal, 2008, 20: 1839-1847.
24. Seo JW, Srisook E, Son HJ, et al. Syntheses of tetrahydroisoquinoline derivatives that inhibit NO production in activated BV-2 microglial cells [J]. Eur J Med Chem, 2008, 43: 1160-1170.
25. Dalence-Guzmán MF, Berglund M, Skogvall S, et al. SAR studies of capsazepinoid bronchodilators. Part 1. The importance of the catechol moiety and aspects of the B-ring structure [J]. Bioorg Med Chem Lett, 2008, 16: 2499-2512.
26. Skogvall S, Dalence-Guzmán MF, Berglund M, et al. Discovery of a potent and long-acting bronchorelaxing capsazepinoid, RESPIR 4-95 [J]. Pulm Pharmacol Ther, 2008, 21: 125-133.
27. Berglund M, Dalence-Guzmán MF, Skogvall S, et al. SAR studies of capsazepinoid bronchodilators. Part 2. Chlorination and catechol replacement in the A-ring [J]. Bioorg Med Chem, 2008, 16: 2513-2528.
28. Berglund M, Dalence-Guzmán MF, Skogvall S, et al. SAR studies of capsazepinoid bronchodilators 3: the thiourea part (coupling region) and the 2-(4-chlorophenyl) ethyl moiety (C-region) [J]. Bioorg Med Chem, 2008, 16: 2529-2540.
29. Zheng MQ, Zhang XY, Zhao M, et al. (3S)-N-(L-aminoacyl)-1,2,3,4- tetrahydroisoquinolines, a class of novel antithrombotic agents: synthesis, bioassay, 3D-QSAR, and ADME analysis [J]. Bioorg Med Chem, 2008, 16: 9574-9587.
30. Malovichko OL, Petrus AS, Krysko AA, et al. Derivatives of 7-amino-1, 2, 3, 4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists [J]. Bioorg Med Chem Lett, 2006, 16: 5294-5297.
31. Pyo MK, Lee DH, Kim DH, et al. Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation [J]. Bioorg Med Chem Lett, 2008, 18: 4110-4114.
32. Pyo MK, Kim JM, Jin JL, et al. Effects of higenamine and its 1-naphthyl analogs. YS-49 and YS-51, on platelet TXA2 synthesis and aggregation [J]. Thromb Res, 2007, 120: 81-86.
33. Sun JJ, Kim HJ, Seo HG, et al. YS49, 1-naphthylmethyl-6,7-dihydroxy-1,2, 3,4-tetrahydroisoquinoline, regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of hemeoxygenase-1 [J]. Life Sci, 2008, 82: 600-607.
34. Kang JH. Salsolinol, a tetrahydroisoquinoline catechol neurotoxin induces human Cu, Zn-superoxidie dismutase modification [J]. J Biochem Mol Biol, 2007, 40: 684-689.
35. Takahashi T, Maruyama W, Deng Y, et al. Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells [J]. J Neural Transm, 1997, 104: 59-66. (Pubitemid 27073229)
36. Kotake Y, Sekiya Y, Okuda K, et al. Cytotoxicity of 17 tetrahydroisoquinoline derivatives in SH-SY5Y human neuroblastoma cells is related to mitochondrial NADH-ubiquinone oxidoreductase inhibition [J]. Neurotoxicol, 2007, 28: 27-32. (Pubitemid 46187254)
37. Kotake Y, Taguchi R, Okuda K, et al. Neuroprotective effect of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins [J]. Brain Res, 2005, 1033: 143-150.
38. Okuda K, Kotake Y, Ohta S. Parkinsonism-preventing activity of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo [J]. Biol Pharm Bull, 2006, 29: 1401-1403.
39. Xiang L, Yang ZJ. Application of amide alkaloids from Portulaca oleracea L. in the preparation of antioxidants and neuron protecting agents: CN, 200810014427.1 [P]. 2008-03-05.
40. Standridge JB. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease [J]. Curr Alzheimer Res, 2006, 3: 95-108.
41. Hu MK, Liao YF, Chen JF, et al. New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins [J]. Bioorg Med Chem, 2008, 16: 1957-1965.
42. Gitto R, Ficarra R, Stancanelli R, et al. Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4- chlorophenyl)-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline AMPAR antagoniste [J]. Bioorg Med Chem, 2007, 15: 5417-5423.
43. Citraro R, Russo E, Gratteri S, et al. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy [J]. Neuropharmacol, 2006, 51: 1058-1067.
44. Gitto R, De Luca L, Pagano B, et al. Synthesis and anticonvulsant evaluation of N-substituted isoquinoline AMPA receptor antagonists [J]. Bioorg Med Chem, 2008, 16: 2379-2384.
45. Fava GA, Fabbri S. Residual symptoms in depression: an emerging therapeutic target [J]. Prog Neuropsychopharmacol Biol Psychiat, 2002, 26: 1019-1027. (Pubitemid 35256092)
46. Jesudason CD, Beavers LS, Cramer JW, et al. Synthesis and SAR of novel histamine H3 receptor antagonists [J]. Bioorg Med Chem Lett, 2006, 16: 3415-3418. (Pubitemid 44226373)
47. Deng XH, Jimmy TX, Liu J, et al. A practical synthesis of enantiopure 7-alkoxy-4-aryl-tetrahydroisoquinoline, a dual serotonin reuptake inhibitor/histamine H3 antagonist [J]. Org Process Res Dev, 2007, 11: 1043-1050.
48. 7 antagonists with potential as antischizophrenic drugs: serominic compounds [J]. Bioorg Med Chem Lett, 2007, 17: 2649-2655.